Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $182000.0.

  • Puma Biotechnology's Other Accumulated Expenses rose 12469.14% to $182000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $182000.0, marking a year-over-year increase of 12469.14%. This contributed to the annual value of $111000.0 for FY2024, which is 7836.26% down from last year.
  • Latest data reveals that Puma Biotechnology reported Other Accumulated Expenses of $182000.0 as of Q3 2025, which was up 12469.14% from $223000.0 recorded in Q2 2025.
  • Puma Biotechnology's 5-year Other Accumulated Expenses high stood at $733000.0 for Q2 2021, and its period low was $81000.0 during Q3 2024.
  • In the last 5 years, Puma Biotechnology's Other Accumulated Expenses had a median value of $316000.0 in 2024 and averaged $366315.8.
  • In the last 5 years, Puma Biotechnology's Other Accumulated Expenses skyrocketed by 13860.47% in 2023 and then crashed by 7836.26% in 2024.
  • Puma Biotechnology's Other Accumulated Expenses (Quarter) stood at $632000.0 in 2021, then plummeted by 65.98% to $215000.0 in 2022, then skyrocketed by 138.6% to $513000.0 in 2023, then tumbled by 78.36% to $111000.0 in 2024, then skyrocketed by 63.96% to $182000.0 in 2025.
  • Its Other Accumulated Expenses was $182000.0 in Q3 2025, compared to $223000.0 in Q2 2025 and $294000.0 in Q1 2025.